Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TORL-3-600 |
| Synonyms | |
| Therapy Description |
TORL-3-600 is an antibody-drug conjugate (ADC) comprising an anti-CDH17 monoclonal antibody linked to MMAE, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 1900). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TORL-3-600 | TORL3-600|TORL 3-600 | TORL-3-600 is an antibody-drug conjugate (ADC) comprising an anti-CDH17 monoclonal antibody linked to MMAE, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 1900). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05948826 | Phase I | TORL-3-600 | First in Human Study of TORL-3-600 in Participants With Advanced Cancer | Active, not recruiting | USA | CAN | 0 |